To validate the prognostic value of SLC7A2 in ovarian cancer, we divided 58 patients in the GSE31245 datasets into two groups using the median mRNA expression level of SLC7A2 as a cutoff point. This evidence concerns the gene SLC7A2 and ovarian cancer.